A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

  1. Green, M.D.
  2. Koelbl, H.
  3. Baselga, J.
  4. Galid, A.
  5. Guillem, V.
  6. Gascon, P.
  7. Siena, S.
  8. Lalisang, R.I.
  9. Samonigg, H.
  10. Clemens, M.R.
  11. Zani, V.
  12. Liang, B.C.
  13. Renwick, J.
  14. Piccart, M.J.
  15. Yang, B.-B.
  16. Bashir, S.
  17. Hill, L.R.
  18. Breddy, J.
  19. Foote, M.A.
  20. Ackland, S.P.
  21. Andreesen, R.
  22. Bashford, J.
  23. Cascinu, S.
  24. Cocconi, G.
  25. Cocquyt, V.
  26. Coleman, R.E.
  27. Dunlop, D.
  28. Grothey, A.
  29. Holmes, F.A.
  30. Koczwara, B.
  31. Lind, M.J.
  32. Lluch, A.
  33. Marques, F.
  34. Miles, D.
  35. Richardson, G.E.
  36. Santoro, A.
  37. Schaafsma, M.R.
  38. Show all authors +
Journal:
Annals of Oncology

ISSN: 0923-7534

Year of publication: 2003

Volume: 14

Issue: 1

Pages: 29-35

Type: Article

DOI: 10.1093/ANNONC/MDG019 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus